Baseline characteristics

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT · Source last updated 2015-12-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      20

   units

   Participants

groups

1. description

   Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51) Induction Chemotherapy: CT backbone of the IRS-III regimen \[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine,and hydrocortisone, coinciding with a cycle of CT. Radiation Therapy: Pts w/ M0 dz OR M+ dz aged \<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \>3y w/ M+ dz rcvd craniospinal irradiation. Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.

   id

   BG000

   title

   Multi-agent Intrathecal & Systemic CT w/ RT (Modified IRS III)

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            0.2

            upper Limit

            19

            value

            2.2

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            11

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            9

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            20

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

      title

      M0

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            1

      title

      M2

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            5

      title

      M3

   description

   Chang staging: M0 is non-metastatic disease. M1 is CSF +ve disease which means that the tumor cells are found floating in the spinal fluid, M2 is localized metastatic disease and M3 is disseminated bulk disease.

   param Type

   NUMBER

   title

   Chang Stage

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice